Impaired Rivaroxaban Clearance in Mild Renal Insufficiency With Verapamil Coadministration: Potential Implications for Bleeding Risk and Dose Selection.

about

Effect of ABCB1 genetic polymorphisms on the transport of rivaroxaban in HEK293 recombinant cell lines.

P2860

Q55662488-656AC3F3-D1A8-4EFF-9647-C314691BC886

P2860

Impaired Rivaroxaban Clearance in Mild Renal Insufficiency With Verapamil Coadministration: Potential Implications for Bleeding Risk and Dose Selection.

Item

http://www.wikidata.org/entity/Q50193651

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Impaired Rivaroxaban Clearance ...... eding Risk and Dose Selection.

@en

Impaired Rivaroxaban Clearance ...... eding Risk and Dose Selection.

@nl

type

Item

label

Impaired Rivaroxaban Clearance ...... eding Risk and Dose Selection.

@en

Impaired Rivaroxaban Clearance ...... eding Risk and Dose Selection.

@nl

prefLabel

Impaired Rivaroxaban Clearance ...... eding Risk and Dose Selection.

@en

Impaired Rivaroxaban Clearance ...... eding Risk and Dose Selection.

@nl

P1476

Impaired Rivaroxaban Clearance ...... eeding Risk and Dose Selection

@en

P2093

Christopher M Rubino

http://www.w3.org/2001/XMLSchema#string

David J Greenblatt

http://www.w3.org/2001/XMLSchema#string

Jerold S Harmatz

http://www.w3.org/2001/XMLSchema#string

Maulik Patel

http://www.w3.org/2001/XMLSchema#string

Wayne T Nicholson

http://www.w3.org/2001/XMLSchema#string

P2860

New oral anticoagulants in patients with nonvalvular atrial fibrillation: a review of pharmacokinetics, safety, efficacy, quality of life, and cost effectiveness

Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban

Pharmacology of anticoagulants used in the treatment of venous thromboembolism

Calcium antagonists.

Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor

Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor.

An open-label study to estimate the effect of steady-state erythromycin on the pharmacokinetics, pharmacodynamics, and safety of a single dose of rivaroxaban in subjects with renal impairment and normal renal function.

Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4.

Oral direct factor Xa inhibitors for stroke prevention in atrial fibrillation.

New oral anticoagulants: comparative pharmacology with vitamin K antagonists.

P304

533-540

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/JCPH.1040

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Christina R Chow

P577

2017-11-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29194698

http://www.w3.org/2001/XMLSchema#string

Impaired Rivaroxaban Clearance in Mild Renal Insufficiency With Verapamil Coadministration: Potential Implications for Bleeding Risk and Dose Selection.

about

P2860

P2860

Impaired Rivaroxaban Clearance in Mild Renal Insufficiency With Verapamil Coadministration: Potential Implications for Bleeding Risk and Dose Selection.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698